RESUMO
A group of 37 postmenopausal women ingested mestranol (MEE) 20 ug daily per 90 days. Cervical mucus, vaginal citology, endometrial biopsy, 17 beta estradiol (E-2) low density lipoprotein-cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C), were determined in all of them before (phase I) and after such treatment (phase II). Besides, the relieve of vasomotor symptoms, fernlike cristallization and pyknotic nuclei cells, increase and 3/4 of the endometrial samples showed proliferation, in phase II. Endogenous circulating E-2 was not disturbed regardless MEE treatment and inverse relationship was attained on circulating lipoproteins, while LDL-C decrease (p = 0.01), HDL-C increase (p = 0.001), after comparing phase I vs. phase II. Chlormadinone acetate (2 mg/day/3 days) was administered at the end of the MEE treatment to avoid endometrial estrogenic persistence. Current studies should be enlarged to support the usage of new dose and regimen of mestranol replacement therapy.
Assuntos
Terapia de Reposição de Estrogênios , Mestranol/administração & dosagem , Pós-Menopausa , Colesterol/sangue , Endométrio/efeitos dos fármacos , Endométrio/patologia , Feminino , Humanos , Mestranol/uso terapêutico , Pessoa de Meia-Idade , Pós-Menopausa/efeitos dos fármacos , Pós-Menopausa/metabolismoRESUMO
Un grupo de 37 mujeres postmenopáusia recibieron mestranol (MEE) 20 ug/d/90 d. En cada una se tomaron muestras de moco cervical citología vaginal, biopsia de endometrio y sangre para medir 17 beta estradiol (E-2), fracciones de baja (LDL-C) y alta HDL-C densidad lipoproteica del colesterol antes (fase I) y después de ese tratamiento (fase II). Además de suprimir la sintomatología vasomotora, el moco endocervical y las células vaginales cariopicnóticas aumentaron y 3/4 de las biopsias presentaron proliferación en la fase II. No se produjo cambio en la concentración de estrógenos natural. La fracción LDL-C disminuyó (p=0.01) y la HLD-C aumentó (p=0.001) al comparar las fases I y II. Acetato de clormadinona fue administrado 2 mg/d/3 d para descamar el endometrio hacia el final del tratamiento con MEE. Para fundamentar esta dosis estrogénica y el nuevo régimen es necesario aumentar la casuística
Assuntos
Pessoa de Meia-Idade , Humanos , Feminino , Estrogênios/metabolismo , Estrogênios/uso terapêutico , Mestranol/administração & dosagem , Mestranol/uso terapêutico , Terapia de Reposição de Estrogênios/métodos , Terapia de Reposição de EstrogêniosRESUMO
É relatado um caso de endometriose que se manifestou inicialmente na coxa. O tumor comprometia a face ântero-superior da coxa direita, era doloroso e aumentava de volume na época menstrual. No entanto, cerca de seis anos após as terapêuticas cirúrgica e hormonal houve recidiva do tumor e evidenciou-se a presença de foco primário, intraperitoneal. Por fim, säo feitas consideraçöes sobre a endometriose, intra e extraperitoneal, e descritas as principais teorias histogenéticas
Assuntos
Adulto , Humanos , Feminino , Endometriose/patologia , Coxa da Perna , Neoplasias Uterinas/patologia , Combinação de Medicamentos , Endometriose/tratamento farmacológico , Linestrenol/uso terapêutico , Mestranol/uso terapêutico , RecidivaRESUMO
A comparative study of Norinyl 1/35 and Brevicon was conducted at the APLAFA clinic in Panama City, Panama. The study sought to evaluate the differences in continuation rates and the frequency of selected side effects which might contribute to method discontinuation. The 300 subjects were randomly allocated to one of the two oral contraceptives. Women in the Brevicon group reported significantly more (p less than 0.05) intermenstrual bleeding, nausea, headaches, dizziness and vaginal discharge than women in the Norinyl 1/35 group. The total discontinuation rate at 12 months was 28.0 for the Norinyl 1/35 group and 46.7 for the Brevicon group, and this difference was significant (p less than .01). Also, significantly more women (p less than .01) in the Brevicon group discontinued for menstrual problems than women in the Norinyl 1/35 group. No pregnancies were reported during this study. While both oral contraceptives appear safe and effective, Norinyl 1/35 was more acceptable to this group of Panamanian women.